Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC
Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer - EurekAlert!
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert!
PSMA PET/CT prior to salvage radiotherapy improves overall survival for prostate cancer patients: Real-world data from an entire country - EurekAlert!
Cell therapy improves overall survival of patients with colorectal cancer - EurekAlert!
New drug combination increases overall survival in patients with PIK3CA-mutated advanced breast cancer - EurekAlert!
Overall survival and quality-of-life superiority in modern phase 3 oncology trials - EurekAlert!
First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients with BRAF-mutated metastatic colorectal cancer - EurekAlert!
Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer - EurekAlert
